Every year in Europe, around 3.2 million hospital patients become sick with Healthcare-Associated Infections (HAI); and 37,000 of these patients die because of HAIs. It is the effect of the "post antibiotic era", as defined by the scientific community; an effect so serious, it has moved the World Health Organisation and the European Parliament to act with urgency.
Copma scrl, an international leader in environmental and health sanitation is able to make a contribution of great importance, thanks to a structured methodology and its commitment to specialised research.
With a significant investment in science and technology research, the innovative stable hygiene system PCHS® was created to effectively combat the proliferation of nosocomial infections.
PCHS® has a dual purpose: to produce hygiene and to reduce infections. To make hospitals a place where people heal and don’t get sick again, and to improve people's quality of life.
"Today we can say with great satisfaction that the surrounding environment will continue to influence us. This time, positively; for our benefit and not our detriment."
Alberto Rodolfi, Copma President
Its outcomes scientifically document the fundamental contribution of the PCHS® system in achieving results of revolutionary value: the use of PCHS® reduces infections by 52%.
PCHS® is the fundamental principle which reduces the transmission of nosocomial infections in real terms. For this to happen on a large scale, and widely in healthcare, it is necessary to:
PCHS® is a safe system, based on natural biological competition activated by specific techniques. It is governed by a method combining economics, scientific process and quality control. The synergy of several factors enables the maximum action of micro-organisms in PCHS® for the control of environmental microbial contamination, and the production of hygiene. It's the stable hygiene system which overcomes the traditional concept of temporary hygiene based on disinfectants, and acts in medical environments in a new way, through a technique of bio-stabilisation. In June 2017, a multicentre research project, involving five universities, was concluded. The research was conducted on a sample of 13,000 patients at seven hospitals.